Drug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-naïve chronic HBV patients

Hepatitis Monthly

Volumn 13, Issue 1, 2013, Pages

  Mahabadi, Mostafa ^a   Norouzi, Mehdi ^a   Alavian, Seyed Moayyed ^b   Samimirad, Katayoon ^a   Azad, Talat Mokhtari ^a   Saberfar, Esmaeil ^c   Mahmoodi, Mahmood ^a   Ramezani, Fatemeh ^a   Karimzadeh, Hadi ^a   Malekzadeh, Reza ^d   Montazeri, Ghodrat ^d   Nejatizadeh, Azim ^e   Ziee, Masoud ^f   Abedi, Farshid ^g   Ataei, Behrooz ^j   Yaran, Majid ^j   Sayad, Babak ^h   Somi, Mohamad Hossein ⁱ   Sarizadeh, Gholamreza ^j   Sanei Moghaddam, Ismaeil ^k   Mansour Ghanaei, Fariborz ^l   Rafatpanah, Houshang ^m   Pourhosseingholi, Mohammad Amin ⁿ   Keyvani, Hossain ^o   Kalantari, Ebrahim ^p   Saberfiroozi, Mehdi ^q   Judaki, Mohammad Ali ^a   Ghamari, Shiva ^a   Daram, Maryam ^a   Fazeli, Zeinab ^a   Goodarzi, Zahra ^c   Khedive, Abolfazl ^a   Moradi, Abdolvahab ^q   Jazayeri, Seyed Mohamad ^a   more..

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Middle East Liver Diseases Center   (Iran)

^c The research and Development Department of Bayerpaul Vaccine And Pharmaceutical Company   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e HORMOZGAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f BIRJAND UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^h GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

ⁱ ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^j Kermanshah Liver Diseases and Hepatitis Research Center   (Iran)

^k TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^l MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^m SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

ⁿ TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^o Gholhack Medical Laboratory   (Iran)

^p SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^q GOLESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

more..

Author keywords

Drug resistance; Hepatitis B virus; Iran; Therapy

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; TELBIVUDINE;

ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; CROSS-SECTIONAL STUDY; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE MUTATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PHYLOGENY; POLYMERASE CHAIN REACTION;

EID: 84874055811     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.6712     Document Type: Article

References (52)

1. Kose S, Turken M, Cavdar G, Akkoclu G. The Effectiveness of Nucleoside Analogues in Chronic Hepatitis B Patients Unresponsive to Interferon Therapy: Our Clinical Trials for One Year. Hepat Mon. 2010;10(4):289-93.
2. Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007;16(4):403-6.
3. Marcellin P, Asselah T. Resistance to adefovir: a new challenge in the treatment of chronic hepatitis B. J Hepatol. 2005;43(6):920-3.
4. Locarnini S, Qi X, Arterburn S, Snow A, Brosgart CL, Currie G, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). J Hepatol. 2005;42(Suppl 2):17.
5. Deny P, Zoulim F. Hepatitis B virus: from diagnosis to treatment. Pathol Biol (Paris). 2010;58(4):245-53.
6. Han Y, Huang LH, Liu CM, Yang S, Li J, Lin ZM, et al. Characterization of hepatitis B virus reverse transcriptase sequences in Chinese treatment naive patients. J Gastroenterol Hepatol. 2009;24(8):1417-23.
7. Liu BM, Li T, Xu J, Li XG, Dong JP, Yan P, et al. Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naive Chinese patients. Antiviral Res. 2010;85(3):512-9.
8. Nguyen MH, Garcia RT, Trinh HN, Nguyen HA, Nguyen KK, Nguyen LH, et al. Prevalence of hepatitis B virus DNA polymerase mutations in treatment-naive patients with chronic hepatitis B. Aliment Pharmacol Ther. 2009;30(11-12):1150-8.
9. Akarsu M, Sengonul A, Tankurt E, Sayiner AA, Topalak O, Akpinar H, et al. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay. J Gastroenterol Hepatol. 2006;21(12):1783-8.
10. Feeney E, Fanning LJ, Horgan M. Baseline genotypic resistance in untreated hepatitis B virus infection. Gastroenterology. 2007;132:35A.
11. Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol. 2006;44(2):283-90.
12. Margeridon-Thermet S, Shulman NS, Ahmed A, Shahriar R, Liu T, Wang C, et al. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis. 2009;199(9):1275-85.
13. Merrill RM, Hunter BD. Seroprevalence of markers for hepatitis B viral infection. Int J Infect Dis. 2011;15(2):e78-121.
14. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007;46(1):254-65.
15. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003;36(6):687-96.
16. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology. 2001;33(6):1527-32.
17. Delaney WET, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol. 2003;77(21):11833-41.
18. Ogata N, Fujii K, Takigawa S, Nomoto M, Ichida T, Asakura H. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in japanese patients with chronic hepatitis B. J Med Virol. 1999;59(3):270-6.
19. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest. 2001;107(4):449-55.
20. Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology. 2000;31(6):1318-26.
21. Amini-Bavil-Olyaee S, Hosseini SY, Sabahi F, Alavian SM. Hepatitis B virus (HBV) genotype and YMDD motif mutation profile among patients infected with HBV and untreated with lamivudine. Int J Infect Dis. 2008;12(1):83-7.
22. Ramezani A, Velayati AA, Roshan MR, Gachkar L, Banifazl M, Keyvani H, et al. Rate of YMDD motif mutants in lamivudine-untreated Iranian patients with chronic hepatitis B virus infection. Int J Infect Dis. 2008;12(3):252-5.
23. Briones C, de Vicente A, Molina-Paris C, Domingo E. Minority memory genomes can influence the evolution of HIV-1 quasispecies in vivo. Gene. 2006;384:129-38.
24. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med. 2005;352(26):2673-81.
25. Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int. 2008;2(2):147-51.
26. Arrese E, Basaras M, Blanco S, Ruiz P, Cisterna R. Monitoring of therapy in patients with chronic hepatitis B virus. Eur J Gastroenterol Hepatol. 2010;22(6):736-40.
27. Curtis M, Zhu Y, Borroto-Esoda K. Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by adefovir. J Infect Dis. 2007;196(10):1483-6.
28. Kim DY, Ahn SH, Chang HY, Shim HY, Heo J, Cho M, et al. 563 Hepatitis B Virus Quasispecies in the Polymerase Gene in Treatment-Naive Chronic Hepatitis B Patients. J Hepatol. 2008;48:S211.
29. Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol. 2006;44(3):593-606.
30. Sheldon J, Ramos B, Garcia-Samaniego J, Rios P, Bartholomeusz A, Romero M, et al. Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity. J Acquir Immune Defic Syndr. 2007;46(3):279-82.
31. Sheldon J, Rodes B, Zoulim F, Bartholomeusz A, Soriano V. Mutations affecting the replication capacity of the hepatitis B virus. J Viral Hepat. 2006;13(7):427-34.
32. Ghany M, Liang TJ. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology. 2007;132(4):1574-85.
33. Reijnders JG, Leemans WF, Hansen BE, Pas SD, de Man RA, Schutten M, et al. On-treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeks. J Viral Hepat. 2009;16(2):113-20.
34. Seifer M, Patty A, Serra I, Li B, Standring DN. Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir. Antiviral Res. 2009;81(2):147-55.
35. Sayan M. Molecular diagnosis of entecavir resistance. Hepat Mon. 2010;10(1):42-7.
36. Alavian SM, Hajarizadeh B, Ahmadzad-Asl M, Kabir A, Lankarani KB. Hepatitis B Virus Infection in Iran: A Systematic Review. Hepat Mon. 2008;8(4):281-94.
37. Hajiani E, Hashemi SJ, Masjedizadeh AR. Seroepidemiology of Hepatitis B Virus Infection in Khuzestan Province, Southwest of Iran. Hepat Mon. 2009;9(1):34-8.
38. Locarnini S, Bowden S. Drug resistance in antiviral therapy. Clin Liver Dis. 2010;14(3):439-59.
39. Nokhodian Z, Kassaian N, Ataei B, Javadi AA, shoaei P, Farajzadegan Z, et al. Hepatitis B Markers in Isfahan, Central Iran: A Population-Based Study. Hepat Mon. 2009;9(1):12-6.
40. Grande-Perez A, Lazaro E, Lowenstein P, Domingo E, Manrubia SC. Suppression of viral infectivity through lethal defection. Proc Natl Acad Sci U S A. 2005;102(12):4448-52.
41. Arias A, Ruiz-Jarabo CM, Escarmis C, Domingo E. Fitness increase of memory genomes in a viral quasispecies. J Mol Biol. 2004;339(2):405-12.
42. Ruiz-Jarabo CM, Arias A, Baranowski E, Escarmis C, Domingo E. Memory in viral quasispecies. J Virol. 2000;74(8):3543-7.
43. Domingo E. Mechanisms of viral emergence. Vet Res. 2010;41(6):38.
44. Domingo E, Escarmis C, Lazaro E, Manrubia SC. Quasispecies dynamics and RNA virus extinction. Virus Res. 2005;107(2):129-39.
45. Ruiz-Jarabo CM, Miller E, Gomez-Mariano G, Domingo E. Synchronous loss of quasispecies memory in parallel viral lineages: a deterministic feature of viral quasispecies. J Mol Biol. 2003;333(3):553-63.
46. Wyatt CA, Andrus L, Brotman B, Huang F, Lee DH, Prince AM. Immunity in chimpanzees chronically infected with hepatitis C virus: role of minor quasispecies in reinfection. J Virol. 1998;72(3):1725-30.
47. Briones C, Domingo E. Minority report: hidden memory genomes in HIV-1 quasispecies and possible clinical implications. AIDS Rev. 2008;10(2):93-109.
48. Briones C, Domingo E, Molina-Paris C. Memory in retroviral quasispecies: experimental evidence and theoretical model for human immunodeficiency virus. J Mol Biol. 2003;331(1):213-29.
49. Jazayeri SM, Carman WF. Virus Escape CTL or B Cell Epitopes? Hepat Mon. 2005;5(4):133-6.
50. Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis. 2006;26(2):162-70.
51. Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol. 2006;44(2):422-31.
52. Cuestas ML, Rivero CW, Minassian ML, Castillo AI, Gentile EA, Trinks J, et al. Naturally occurring hepatitis B virus (HBV) variants with primary resistance to antiviral therapy and S-mutants with potential primary resistance to adefovir in Argentina. Antiviral Res. 2010;87(1):74-7.